1 |
Choi GS. Hair characteristics and androgenetic alopecia in Koreans. J Korean Med 2013;56:45-54.
|
2 |
Valente Duarte de Sousa IC, Tosti A. New investigational drugs for androgenetic alopecia. Expert Opin Investig Drugs 2013;22:573-89.
DOI
|
3 |
Han JH, Kwon OS, Chung JH, et al. Effect of minoxidil on proliferation and apoptosis in dermal papilla cells of human hair follicle. J Dermatol Sci 2004;34(2):91-8.
DOI
|
4 |
Kwon OE, Ku BS, Lee YK, et al. Histopathologic gradings correlate with clinical prognostic factors and therapeutic effects in patient with alopecia areata. Korean J Dermatol 2007;45(2):111-8.
|
5 |
Giustizieri ML, Albanesi C, Fluhr J, et al. H1 histamine receptor mediated inflammatory responses in human keratinocytes. J Allergy Clin Immunol 2004;114(5):1176-82.
DOI
|
6 |
Smith A, Trueb R M, Theiler M, et al. High relapse rates despite early intervention with intravenous methylprednisolone pulse therapy for severe childhood alopecia areata. Pediatr Dermatol 2015;32:481.
DOI
|
7 |
Randall VA. Androgens and hair growth. Dermatol Ther 2008;21(5):314-28.
DOI
|
8 |
Ligia B, Beata B, Dominika W, et al. New aspects of the treatment of alopecia areata. Postepy Dermatol Alergol 2014;31:262-5.
|
9 |
Messenger AG, Mckillop J, Farrant P, et al. British association of Dermatologists' guidelines for the management of alopecia areata 2012. Br J Dermatol 2012;166(5):916-26.
DOI
|
10 |
Inui S, Nakajima T, Toda N, et al. Fexofenadine hydrochloride enhances the efficacy of contact immunotherapy for extensive alopecia areata: Retrospective analysis of 121 cases. J Dermatol 2009;36(6):323-7.
DOI
|
11 |
Ito T. Advances in the management of alopecia areata. J Dermatol 2012;39(1):11-7.
DOI
|
12 |
Santos Z, Avci P, Hamblin M R. Drug Discovery for alopecia: gone today, hair tomorrow. Expert Opin Drug Discov 2015;10(3):269-92.
DOI
|
13 |
Metz M, Grundmann S, Stander S. Pruritus: an overview of current concepts. Vet Dermatol 2011;22(2):121-31.
DOI
|
14 |
Biran R, Zlotogorski A, Ramot Y. The genetics of alopecia areata: New approaches, new findings, new treatments. J Dermatol Sci 2015;78(1):11-20.
DOI
|
15 |
Poqatzki-Zahn E, Marziniak M, Schneider G, et al. Chronic pruritus:targets, mechanisms and therapies. Drug News Perspect 2008;21(10):541.
DOI
|
16 |
Leslie TA, Greaves, M.W, Yosiporitch, G. Current topical and systemic therapies for itch. Handb Exp Pharmacol 2015;226:337-56.
|
17 |
Freyscjmodt-Paul P, Happle R, Hoffman R. Alopecia areata in animal models-new insights into pathogenesis and treatment of a T cell-medicated autoimmune disorder. J Dtsch Drmatol Ges 2004;2(4):260-73.
DOI
|
18 |
Schumacher S, Kietzmann M, Stark H, et al. Unique immunomodulatory effects of azelastine on dendritic cells in vitro. Naunyn Schmiedebergs Arch Pharmacol 2014;387(11):1091-9.
DOI
|
19 |
Alkhalifah A, Alsantali A, Wang E, et al. Alopecia areata update Part II. treatment. J Am Acad Dermatol 2010;62(2):191-202.
DOI
|
20 |
American Hair Loss Association. Available from www.amercianhariloss.org. Accessed April 2, 2016
|
21 |
Korean Society Hair Restoration Treatment. Available from www.kshrt.or.kr. Accessed April 2, 2016
|
22 |
Korean Dermatological Association. Available from www.derma.or.kr. Accessed April 2, 2016
|
23 |
Totoda M, Makino T, Kagoura M, et al. Expression of neuropeptidedegrading enzymes in alopecia areata: an immunohistochemical study. Br J Dermatol 2001;144(1):46-54.
DOI
|